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Abstract
Background: Metals are known endocrine disruptors and have been linked to cardiometabolic diseases via multiple
potential mechanisms, yet few human studies have both the exposure variability and biologically-relevant phenotype data
available. We sought to examine the distribution of metals exposure and potential associations with cardiometabolic risk
factors in the “Modeling the Epidemiologic Transition Study” (METS), a prospective cohort study designed to assess energy
balance and change in body weight, diabetes and cardiovascular disease risk in five countries at different stages of social
and economic development.
Methods: Young adults (25–45 years) of African descent were enrolled (N= 500 from each site) in: Ghana, South Africa,
Seychelles, Jamaica and the U.S.A. We randomly selected 150 blood samples (N = 30 from each site) to determine
concentrations of selected metals (arsenic, cadmium, lead, mercury) in a subset of participants at baseline and to
examine associations with cardiometabolic risk factors.
Results: Median (interquartile range) metal concentrations (μg/L) were: arsenic 8.5 (7.7); cadmium 0.01 (0.8); lead
16.6 (16.1); and mercury 1.5 (5.0). There were significant differences in metals concentrations by: site location, paid
employment status, education, marital status, smoking, alcohol use, and fish intake. After adjusting for these covariates
plus age and sex, arsenic (OR 4.1, 95% C.I. 1.2, 14.6) and lead (OR 4.0, 95% C.I. 1.6, 9.6) above the median values were
significantly associated with elevated fasting glucose. These associations increased when models were further adjusted
for percent body fat: arsenic (OR 5.6, 95% C.I. 1.5, 21.2) and lead (OR 5.0, 95% C.I. 2.0, 12.7). Cadmium and mercury were
also related with increased odds of elevated fasting glucose, but the associations were not statistically significant. Arsenic
was significantly associated with increased odds of low HDL cholesterol both with (OR 8.0, 95% C.I. 1.8, 35.0) and without
(OR 5.9, 95% C.I. 1.5, 23.1) adjustment for percent body fat.
Conclusions: While not consistent for all cardiometabolic disease markers, these results are suggestive of potentially
important associations between metals exposure and cardiometabolic risk. Future studies will examine these associations
in the larger cohort over time.
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There is increasing evidence that environmental chemicals
may be contributing to the risk of diabetes [1], obesity [2],
and cardiovascular disease [3]. Approximately 40% of adults
in the U.S. have diabetes or pre-diabetes [4] and about 70%
of this risk can be attributed to obesity [5,6] which is due, in
part, to underlying genetics, nutrition, and lifestyle factors.
Almost 35% of adults in the U.S. are obese [7] and, world-
wide, the prevalence of obesity and of diabetes are increasing
at alarming rates in industrialized and developing countries
alike [8]. However, the rapid rise in obesity rates may not be
explained solely by genetics and lifestyle factors. Environ-
mental toxicants have been implicated as “obesogens” [9,10]
and risk factors for diabetes [11,12] and cardiovascular dis-
ease [3]. Numerous questions remain, however, regarding
the timing of critical windows of exposure, susceptible
populations at risk, and biological mechanisms of effect.
Toxic metals (arsenic, cadmium, lead, mercury) are ubi-
quitous environmental contaminants that can cause a wide
range of adverse health effects in humans [13,14]. Metals
have been identified as endocrine disruptors [15,16] and,
as such, potential etiologic factors with respect to dia-
betes. Exposure to metals may result in abnormal glucose
metabolism, in turn increasing the risk of developing dia-
betes, through several plausible mechanisms [11], such as
the induction of oxidative stress or interference in signal
transduction or gene expression, resulting in beta-cell dys-
function and insulin resistance [17,18]. Metals have also
been implicated in influencing estrogen receptor-mediated
signaling [19] and may disrupt the glucocorticoid re-
ceptor [20], which regulates a wide range of biological
processes in humans, including insulin sensitivity. It is also
possible that reverse causality is at play, i.e., the existence
of diabetes or pre-diabetes alters the metabolism of metals
so that higher concentrations in the body result. Experi-
mental evidence, however, suggests that insulin resistance
and oxidative stress can be induced by metals, providing
biological plausibility to metals-induced diabetes [17].
Metals have also been implicated in the risk of cardio-
vascular disease [21] which itself is a leading cause of mor-
bidity and mortality. The cardiovascular effects of metals
are related to the increased oxidative stress and inflamma-
tion resulting from the high affinity of metals for binding
sulfhydryl groups thereby reducing oxidative defense mech-
anisms [22]. In vivo and in vitro studies have shown that
metals may exert these effects through increased throm-
bosis, vascular smooth muscle dysfunction, endothelial
dysfunction, dyslipidemia, and immune and mitochon-
drial dysfunction [23]. In epidemiologic studies, metals
have been associated with hypertension, impaired kidney
function, and peripheral arterial disease as well as all-cause
and cardiovascular mortality [24-27].
Metabolic syndrome, a clustering of physiologic ab-
normalities (central obesity, dyslipidemia, hyperglycemia,
hypertension) and a precursor of diabetes and cardiovas-
cular disease, has also been associated with metals expo-
sures in cross-sectional studies [28,29]. Thus far, however,
the human evidence is limited and there is little under-
standing of the underlying etiology. The underlying patho-
physiology connecting the different aspects of metabolic
syndrome is an area of active interest and research, but it
is clear that adiposity and insulin resistance play an im-
portant role [30]. Adipose tissue, as an important endo-
crine organ that modulates metabolism, inflammation and
endothelial function, has been recognized in the develop-
ment of metabolic syndrome, type 2 diabetes, and cardio-
vascular disease [31] and the state of obesity, itself, is an
independent risk factor for cardiovascular disease [32] and
type 2 diabetes [33]. However, the existence of “metabolic-
ally healthy” obese and “metabolically obese” normal weight
phenotypes (31.7% of obese and 23.5% of normal weight
adults in NHANES 1999–2004 [34]) indicate that there is
considerable unexplained variation in these associations
[35,36] which is not explained by diet and physical activity
[37]. Although, others have shown that there is no healthy
pattern of increased weight [38]. Given the sheer magni-
tude of the obesity, type 2 diabetes, and cardiovascular dis-
ease epidemics, it is imperative to consider a potential role
of non-traditional risk factors, such as environmental che-
micals, to better understand their contribution to the glo-
bal disease burden.
To date, it has been difficult to assess the cardiometabolic
effects of environmental metals exposure in human popula-
tions given the lack of specific outcome measurements and
control of potential confounding variables in existing obser-
vational data and the inherent difficulty of testing these hy-
potheses through clinical trials. Many studies have focused
on body mass index (BMI) and there is little information
on the biologically-relevant phenotypes of obesity (e.g. fat
distribution, fat/lean mass percentages) or the mechanistic
intermediate markers of metabolic syndrome.
The objectives of this study were to: i) examine the dis-
tribution of selected blood metals (arsenic, cadmium, lead,
mercury) and ii) evaluate the independent associations of
blood metals with clinical markers of cardiometabolic risk
in a cohort of young adults of African descent living in five
countries across a range of social and economic devel-
opment. In addition to the extensive phenotype data and
stored biological specimens already available on this large
sample population, a major strength is the widespread geo-
graphic distribution of the study sites which may underlie
largely different exposures across the sites.
Methods
Study population
The “Modeling the Epidemiologic Transition Study”
(METS) is a prospective cohort study designed to assess
the association between physical activity levels and relative
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risk in five population-based samples at different stages of
social and economic development [39]. Twenty-five hun-
dred (2,500) young adults, age 25–45 years, were enrolled
between January 2010 and September 2011 with 500 par-
ticipants (~50% male) from each of five sites: rural Ghana
(Kumasi), urban South Africa (Cape Town), the island na-
tion of Seychelles (Victoria), urban Jamaica (Kingston) and
the suburban Chicago area (Maywood, IL) of the United
States of America (U.S.A.). The populations sampled are
all of African descent and represent a range of social and
economic development as defined by the United Nations
Human Development Index (HDI) 2011 [40]: Ghana
(HDI=0.541) as a lower “medium” HDI country, South
Africa (0.619) as “medium”, Jamaica (0.727) and Seychelles
(0.773) as “high”, and the U.S.A. (0.910) as “very high”.
The present study includes a subset of 150 individuals
from the cohort with metals concentrations measured in
randomly selected baseline blood samples.
Extensive baseline data collection included: anthropomet-
rics, estimates of body composition by bioelectrical imped-
ance analysis, blood pressure, physical activity/inactivity by
accelerometry and the World Health Organization Global
Physical Activity Questionnaire [41,42], dietary intake by
two 24-hour recalls, smoking and alcohol consumption his-
tory, self- and family medical history, and measures of em-
ployment history, occupation, education and wealth using
the World Bank’s Core Welfare Indicators Questionnaire
[43]. Fasting blood samples were collected and analyzed
for glucose, lipids, C-reactive protein, and cystatin C.
Yearly follow-up examinations include measurement of
body weight, blood pressure and change in medical his-
tory. Participants have been examined annually for the
past two-to-three years and will continue to be followed
for assessment of change in body weight and composition
and diabetes and cardiovascular disease risk. Exclusion
criteria for METS included: individuals with obvious in-
fectious diseases (including active malaria), HIV-positive
individuals, pregnant or lactating women, and individuals
with conditions which prevented them from engaging
in normal day-to-day physical activities (such as severe
osteo- or rheumatoid arthritis or lower extremity dis-
ability). The research protocol was approved by the Hu-
man Subjects Committees of the participating institutions.
Exposure assessment
We randomly selected 150 baseline samples from archived
whole blood specimens (n=30 per site) to be measured
for concentrations of arsenic, cadmium, lead, and mer-
cury. Venous blood samples were collected in 6-ml cap-
acity plastic lavender top hematology Vacutainer™ tubes
with EDTA as an anticoagulant (BD #367863, Becton
Dickinson, Franklin Lakes, NJ) and mixed by inverting
gently five times. Whole blood (0.5 ml) was transferred
to 2-ml polypropylene microcentrifuge tubes with screw
caps (Fisherbrand™ #02-682-558, Fisher Scientific Com-
pany L.L.C., Pittsburgh, PA), stored at −80°C. Samples were
shipped on dry ice to the Harvard School of Public Health
Trace Metals Laboratory (Boston, MA) for analysis.
All samples were handled in a Class 10,000 clean room
under a Class 100 clean hood. All glass and plastic ware
were cleaned by soaking in 10% HNO3 for 24 hours and
rinsing several times with deionized water. Blood samples
were weighed and digested in 1 ml of ultrapure concen-
trated HNO3 acid for 24 hours and then diluted to 5 ml
with deionized water after the addition of 0.5 ml of 30%
ultrapure hydrogen peroxide. Samples were analyzed using
a dynamic reaction cell-inductively coupled plasma mass
spectrometer (DRC-ICP-MS, Elan 6100, Perkin Elmer,
Norwalk, CT). A mixed solution of 50 ng/ml In (for cad-
mium), 50 ng/ml Lu (for lead) and 150 ng/ml Te (for ar-
senic) in 5% HNO3 were used as the internal standards.
This solution was mixed with calibration standards and
samples on-line using a mixing tee and a mixing coil.
Samples were analyzed by the external calibration method
using seven standards with concentrations ranging from 0
to 10 ng/ml. Quality control measures included: analysis
of initial calibration verification standard, continuous cali-
bration standard, procedural blanks, duplicate samples,
spiked samples, National Institute of Standard and Tech-
nology Standard Reference Material (NIST SRM) 1643e-
trace elements in water and NIST SRM955b-lead in blood.
Results given were the average of five replicate mea-
surements. The limits of detection (ng/ml) in blood
for this procedure are: arsenic (0.02); cadmium (0.01);
and lead (0.01). Total mercury was analyzed using the
Direct Mercury Analyzer 80 Tricell (Milestone Inc.,
Monroe, CT) with a detection limit equal to 0.0015 ng/ml.
Statistical analysis
Participant characteristics were summarized by sex: overall
and by site. Blood metals concentrations were summarized
overall and by site for each metal and by participant char-
acteristics. For metals levels less than the limit of detec-
tion (LOD), a random number between 0 and LOD was
substituted according to a uniform distribution. Next,
metals concentrations were summarized for subjects with
and without each of 11 recognized cardiometabolic disease
risk factors dichotomized using standard clinical cut-points.
Metabolic syndrome is diagnosed based on abnormalities
in specific clustered clinical cardiometabolic measures that
are associated with increased risk for diabetes and cardio-
vascular disease [44]. However, there are no specific cutoffs
for populations of African descent, so we used cutoffs
values for Europeans as suggested by the International
Diabetes Federation [45]. Logistic regression was used to
describe associations between metals exposure (dichoto-
mized at the median) and cardiometabolic risk factors and
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sented. The main covariates of interest were determined a
priori based on biological considerations (age, sex, smoking,
alcohol use, fish intake, percent body fat, physical activity)
and others (education, marital status, paid employment sta-
tus, site location) included using statistical considerations if
they were significant (p=0.1) in bivariate models.
Final models were adjusted for “core” variables includ-
ing: age, sex, and site location. “Fully-adjusted” models add-
itionally included: education, paid employment, marital
status smoking, alcohol use, and fish intake. Since adi-
posity may be a mediator, modifier, or outcome as a result
of exposure to environmental chemicals, we did not adjust
our initial models for BMI or other markers of excess body
fat. However, we next additionally adjusted “core” and
“fully-adjusted” models for percent body fat. All analyses
were performed using STATA® version 11.2 (Copyright
1985–2009, StataCorp LP College Station, Texas USA).
Results
As a result of the parent (METS) study design, partici-
pant characteristics varied widely across sites (Table 1).
Since baseline blood samples (N=30 per site) were chosen
randomly, the distribution of participants by sex within
each site is not uniform; however, overall there were 74
males (49%) and 76 females (51%) participants included
with mean (±SD) age of 34.7 (±6.0) and 35.2 (±6.2) years,
respectively. Forty-nine percent (N=74) of participants
were classified as overweight and 29% (N=44) as obese by
BMI; similarly, 49% had signs of abdominal adiposity mea-
sured by sex-specific elevated waist circumference.
Median (interquartile range) metals concentrations (μg/L)
were: arsenic 8.5 (7.7); cadmium 0.01 (0.8); lead 16.6
(16.1); and mercury 1.5 (5.0). Overall, metals were sig-
nificantly correlated with each other, for example: arsenic
was significantly correlated with: lead (ρ= 0.3, p < 0.001),
cadmium (ρ=0.5, p<0.00001), and mercury (ρ=0.6, p<
0.00001). However, the strengths of these correlations var-
ied between sites with the highest correlations among the
metals observed in Jamaica and the lowest correlations
among the metals in the U.S. (data not shown).
Overall, almost 63% and over 15% of samples, respect-
ively, for cadmium and mercury were below the limits of
detection (Table 2). No samples had undetectable levels
of arsenic and less than one percent had undetectable
levels of lead. As expected, metals concentrations differed
s i g n i f i c a n t l yb ys i t el o c a t i o n .G h a n ah a dt h eh i g h e s tm e d i a n
blood lead levels and the Seychelles had the highest median
blood levels of arsenic and mercury. Twenty-three percent
(N=7) of Ghanaian participants, representing 20% (N=2)
and 25% (N =5) of men and women, respectively, had
blood lead levels >10 μg/dL and one (3%) female partici-
pant had a blood lead level >25 μg/dL. Forty-three percent
of Ghanaians had blood lead levels >3.6 μg/dL (95th
percentile of NHANES 2009–2010 levels for ages 20 years
and above) [46] and 17% of Seychellois were also above
this threshold. Interestingly, one participant at each site in
the U.S.A. and South Africa also exceeded the NHANES
95th percentile for blood lead while none in Jamaica did.
There were no significant differences in blood metals
by age group or sex, although in both the U.S. and South
African samples women tended to have lower lead levels
than the men. There were also significant differences
in metals concentrations by: employment status, edu-
cation, marital status, smoking, alcohol use, and fish
intake (Table 3). Those participants reporting paid em-
ployment in the previous month had higher blood metals
concentrations than those who did not work and these dif-
ferences were significantly significant for all of the metals,
except lead, suggesting that occupation may be related to
exposure. However, there were no significant differences
by employment type: non-manual, skilled manual, or un-
skilled manual labor. Most participants (73%) in this sub-
sample of the cohort reported being “never smokers” and
only 18% (N=27) reported being “current” (≥1/day for at
least one year) smokers. Among smokers, the mean (±SD)
number of cigarettes smoked per day was 6.9±4.2 (range
1–20) and this did not differ significantly by location (p=
0.84). As would be expected, cadmium levels were signifi-
cantly higher among current or occasional smokers com-
pared to ex- or never smokers (p=0.008).
Table 4 shows unadjusted associations between metals
and cardiometabolic risk factors. Less than 3% and 7% of
participants in the sample, respectively, reported having
diabetes or high blood pressure. However, 34% (N= 51)
had elevated fasting blood glucose levels and 16% (N=24)
had elevated systolic and 15.3% (N=23) had elevated dia-
stolic blood pressure by baseline clinical measurement.
Additionally, 30% (N=45) had elevated triglyceride levels
and more than 31% (N=47) had low HDL cholesterol
while more than 67% (N=101) had elevated LDL choles-
terol. Geometric mean (95% CI) metals levels were higher
in those participants with elevated fasting glucose. Arsenic
and mercury levels were also significantly higher in those
with elevated triglyceride to HDL ratios.
Adjusting for age, sex, and site location, arsenic (OR 3.0,
95% C.I. 1.0, 8.6), cadmium (OR 2.1, 95% C.I. 1.0, 4.2), lead
(OR 3.3, 95% C.I. 1.5, 7.1), and mercury (OR 2.0, 95% C.I.
0.7, 5.7) were associated with an increased odds of ele-
vated fasting glucose (Table 5); these associations were
stronger upon adjustment for additional covariates and
including percent body fat (Tabl e6 ) .A d d i t i o n a l l y ,a r s e n i c
above the median value was associated with significantly in-
creased odds low HDL cholesterol (OR 1.22, 95% C.I. 1.07,
1.38). Mercury above the median was associated with in-
creased odds for 10 of the 11 cardiometabolic risk factors,
but none of these associations was statistically signifi-
cant. While these results, and several other non-significant
Ettinger et al. Environmental Health 2014, 13:90 Page 4 of 15
http://www.ehjournal.net/content/13/1/90associations, are in the hypothesized direction of increased
risk, there were also some statistically significant (and non-
significant) negative associations that do not support our
hypotheses.
Discussion
These data, while not entirely consistent, are suggestive
of potentially important associations between blood metals
concentrations and cardiometabolic risk. In particular, a
statistically significant relationship was observed between
arsenic and lead exposure and increased risk for elevated
fasting glucose which was stronger upon adjustment
for adiposity. This is consistent with previously published
cross-sectional studies examining these associations
[28,47,48]. Additionally, arsenic was significantly asso-
ciated with increased odds of low HDL cholesterol both
Table 1 Distribution of participant characteristics by sex: overall and by site location
Overall U.S.A. South Africa Ghana Jamaica Seychelles
Mean± SD
(or %)
Mean± SD
(or %)
Mean± SD
(or %)
Mean± SD
(or %)
Mean±SD
(or %)
Mean±SD
(or %)
p-value*
Male N= 74 N= 10 N= 15 N=10 N=24 N= 15
Age (years) 34.7±6.0 34.8±6.4 33.7±6.0 36.5±6.4 34.5± 6.4 34.6±5.3 0.9
Education (years) 11.2±2.2 12.7±1.4 10.3±1.9 9.2± 2.4 11.1± 1.9 12.8±1.7 <0.0001
Weight (kg) 74.0± 17.2 89.1± 20.2 64.1± 16.4 59.3±6.0 75.4±12.9 81.2±15.3 <0.0001
Height (cm) 172.8±7.4 171.5±4.3 166.4±6.1 170.3±6.4 177.7±6.5 173.9± 7.2 <0.0001
Body Mass Index (kg/m
2) 24.7±5.4 30.4±7.2 22.9±4.5 20.5±2.2 23.9± 4.1 26.9±4.9 <0.0001
Waist circumference (cm) 83.2± 13.5 93.5± 20.6 79.3± 12.3 74.2±5.4 81.8±10.6 88.8±11.5 0.004
Fat Mass (kg) 20.2± 11.1 31.5± 13.6 18.7±9.7 10.1±5.7 19.4± 8.5 22.4±10.9 <0.0001
Percent Body Fat (%) 25.9±9.2 34.0±7.8 27.7±8.1 16.8±8.9 24.8± 8.2 26.4±8.0 <0.0001
Overweight (BMI ≥25) 40.5 70.0 26.7 10.0 37.5 60.0 0.02
Obese (BMI ≥30) 14.9 60.0 6.7 0.0 4.2 20.0 <0.0001
Employed 74.3 60.0 26.7 90.0 87.5 100.0 <0.0001
Married (or Living as Married) 51.4 40.0 40.0 90.0 37.5 66.7 0.03
Smoking (ever) 37.8 40.0 66.7 0.0 33.3 40.0 0.02
Alcohol (≥12 drinks/year) 68.9 60.0 40.0 40.0 83.3 100.0 <0.0001
Fish Intake (≥1 serving/day) 55.4 20.0 20.0 80.0 62.5 86.7 0.0001
Physical Activity (<21.5 min/day) 60.8 80.0 33.3 50.0 70.8 66.7 0.09
Female N= 76 N= 20 N= 15 N=20 N= 6 N= 15
Age (years) 35.2±6.2 37.1±5.9 33.7±6.8 33.2±6.5 37.2± 4.6 36.0±5.8 0.2
Education (years) 11.0±4.3 14.1±2.4 9.7± 3.4 6.9± 3.5 10.3± 1.8 14.0±3.7 <0.0001
Weight (kg) 74.8± 20.5 77.7± 19.0 81.6± 24.3 67.8± 16.1 91.2±32.2 67.1±12.3 0.03
Height (cm) 161.5±7.5 164.3±8.8 160.1±5.9 157.5±7.2 165.8±8.3 162.8± 4.8 0.02
Body Mass Index (kg/m
2) 28.7±7.5 28.6±5.3 31.9±9.5 27.3±6.5 33.3±12.1 25.4±5.2 0.07
Waist circumference (cm) 90.4± 14.9 90.9± 14.7 95.7± 15.3 88.5± 13.3 101.1± 21.2 82.6±10.2 0.05
Fat Mass (kg) 30.5± 13.8 32.3± 11.5 37.7± 15.5 25.3± 12.0 39.0±21.7 24.6±8.5 0.01
Percent Body Fat (%) 39.4±8.7 40.9±6.8 45.1±6.9 35.9± 10.3 40.4±10.3 35.8±6.8 0.009
Overweight (BMI ≥25) 57.9 50.0 80.0 45.0 83.3 53.3 0.2
Obese (BMI ≥30) 43.4 50.0 46.7 45.0 50.0 26.7 0.7
Employed 52.6 60.0 6.7 50.0 33.3 100.0 <0.0001
Married (or Living as Married) 47.4 20.0 53.3 65.0 50.0 53.3 0.06
Smoking (ever) 15.8 40.0 6.7 0.0 33.3 6.7 0.002
Alcohol (≥12 drinks/year) 42.1 55.0 20.0 35.0 66.7 46.7 0.2
Fish Intake (≥1 serving/day) 51.3 40.0 13.3 75.0 33.3 80.0 0.0002
Physical Activity (<21.5 min/day) 84.2 90.0 93.3 80.0 83.3 73.3 0.6
*p-value from analysis of variation by site.
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was associated with increased odds for 10 of the 11 cardio-
metabolic risk factors though these associations were
not statistically significant. We propose to further evaluate
these preliminary associations in the larger METS cohort
of 2,500 individuals at baseline and also assess changes in
risk over time taking advantage of the longitudinal follow-
up of the cohort.
There is increasing concern that unintended exposures
to environmental contaminants may be adversely affect-
ing human health. The association between environmental
contaminants and diabetes, obesity, and cardiovascular
disease is an emerging area of interest in the field of
environmental health sciences [2,49]. Despite the con-
ventional focus on clinical and modifiable lifestyle risk
factors, the incidence of cardiometabolic diseases con-
tinues to increase at alarming rates bringing the focus
on environmental risk factors to the forefront. Simultan-
eously, there is increasing recognition that many chronic
diseases have their origins in fetal life [50] and exposure
to endocrine disrupting chemicals, such as metals, during
critical windows of fetal development may be important
contributing factors that “program” individuals to be at in-
creased risk for metabolic disturbances by altering normal
glycemic control or adipocyte differentiation [51,52]. None-
theless, important questions remain about timing of critical
Table 2 METS blood metals concentrations, overall and by site location
Selected percentiles
N GM (95% CI) %< LOD* Minimum** 25th (95% CI) 50th (95% CI) 75th (95% CI) Maximum
Overall
Lead (μg/dL) 150 1.55 (1.30, 1.85) 0.7 0.001 0.97 (0.76, 1.09) 1.66 (1.34, 1.93) 2.60 (2.25, 2.98) 31.82
Cadmium (μg/L) 150 0.03 (0.02, 0.04) 62.7 0.000004 0.004 (0.003, 0.005) 0.008 (0.007, 0.009) 0.83 (0.29, 1.08) 3.08
Arsenic (μg/L) 150 8.23 (7.50, 9.02) 0.0 2.51 4.92 (4.57, 5.87) 8.48 (7.62, 10.07) 12.76 (11.59, 14.99) 26.85
Mercury (μg/L) 150 0.85 (0.52, 1.37) 15.3 0.001 0.22 (0.07, 0.51) 1.49 (1.01, 2.23) 5.31 (3.42, 15.38) 70.36
U.S.A.
Lead (μg/dL) 30 0.80 (0.61, 1.05) 0.0 0.22 0.44 (0.36, 0.68) 0.74 (0.47, 1.14) 1.28 (0.95, 1.89) 6.05
Cadmium (μg/L) 30 0.15 (0.07, 0.31) 26.7 0.005 0.009 (0.006, 0.20) 0.29 (0.14, 0.60) 0.83 (0.36, 1.03) 1.21
Arsenic (μg/L) 30 3.97 (3.62, 4.35) 0.0 2.61 3.33 (3.02, 3.55) 3.83 (3.42, 4.56) 4.72 (3.94, 5.24) 8.47
Mercury (μg/L) 30 0.07 (0.03, 0.20) 33.3 0.001 0.007 (0.002, 0.07) 0.15 (0.01, 0.36) 0.69 (0.22, 1.22) 24.46
South Africa
Lead (μg/dL) 30 1.45 (1.22, 1.74) 0.0 0.58 0.99 (0.82, 1.23) 1.42 (1.16, 1.86) 1.99 (1.71, 2.74) 3.79
Cadmium (μg/L) 30 0.00 (0.00, 0.01) 93.3 0.000004 0.002 (0.0006, 0.003) 0.004 (0.003, 0.007) 0.008 (0.005, 0.01) 1.10
Arsenic (μg/L) 30 5.65 (5.18, 6.16) 0.0 3.98 4.71 (4.32, 5.11) 5.43 (4.81, 6.52) 6.88 (5.84, 7.71) 9.52
Mercury (μg/L) 30 0.05 (0.02, 0.15) 40.0 0.001 0.005 (0.001, 0.03) 0.09 (0.01, 0.33) 0.47 (0.15, 0.97) 35.10
Ghana
Lead (μg/dL) 30 3.12 (1.53, 6.38) 3.3 0.001 2.02 (1.35, 2.79) 2.96 (2.14, 3.96) 5.90 (3.59, 25.97) 31.82
Cadmium (μg/L) 30 0.00 (0.00, 0.01) 100.0 0.00003 0.004 (0.001, 0.005) 0.006 (0.004, 0.007) 0.008 (0.006, 0.009) 0.01
Arsenic (μg/L) 30 11.17 (9.69, 12.87) 0.0 2.51 10.30 (7.47, 11.11) 11.68 (10.46, 12.57) 14.00 (12.31, 15.61) 20.70
Mercury (μg/L) 30 1.56 (1.01, 2.42) 3.3 0.009 1.08 (0.73, 1.42) 1.87 (1.33, 2.29) 2.93 (2.14, 4.13) 11.25
Jamaica
Lead (μg/dL) 30 0.96 (0.77, 1.19) 0.0 0.25 0.69 (0.44, 0.95) 1.01 (0.77, 1.24) 1.39 (1.06, 2.01) 2.57
Cadmium (μg/L) 30 0.01 (0.00, 0.04) 76.7 0.0002 0.004 (0.001, 0.004) 0.005 (0.00, 0.01) 0.17 (0.01, 1.10) 3.08
Arsenic (μg/L) 30 9.24 (8.37, 10.19) 0.0 6.35 7.89 (6.99, 8.49) 8.61 (8.09, 9.65) 10.23 (8.97, 14.20) 19.02
Mercury (μg/L) 30 2.43 (1.82, 3.25) 0.0 0.22 1.66 (0.82, 2.40) 2.54 (2.19, 3.60) 3.84 (3.39, 6.41) 8.33
Seychelles
Lead (μg/dL) 30 2.56 (2.26, 2.90) 0.0 1.46 1.96 (1.72, 2.43) 2.49 (2.21, 2.80) 3.23 (2.60, 3.92) 6.71
Cadmium (μg/L) 30 0.47 (0.21, 1.06) 16.7 0.001 1.04 (0.01, 1.15) 1.17 (1.11, 1.22) 1.27 (1.19, 1.42) 1.56
Arsenic (μg/L) 30 16.29 (14.93, 17.77) 0.0 10.55 13.98 (11.93, 15.56) 16.38 (14.40, 17.05) 18.59 (16.59, 23.10) 26.85
Mercury (μg/L) 30 28.47 (23.03, 35.18) 0.0 9.20 18.16 (13.70, 24.45) 28.34 (22.34, 39.19) 48.58 (31.77, 60.84) 70.36
*Limits of detection (ng/ml): Lead (0.01); Cadmium (0.01); Arsenic (0.02); Mercury (0.0015).
**For levels less than LOD: substituted a random number between 0 and LOD (according to uniform distribution).
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http://www.ehjournal.net/content/13/1/90Table 3 Geometric mean (95% confidence interval) blood metals concentrations by participant characteristics
Lead (μg/dL) Cadmium (μg/L) Arsenic (μg/L) Mercury (μg/L)
Variable N (%) GM (95% CI) p-value GM (95% CI) p-value GM (95% CI) p-value GM (95% CI) p-value
Site Location
U.S.A. 30 (20) 0.80 (0.61, 1.05) <0.00001 0.15 (0.07, 0.31) <0.00001 3.97 (3.62, 4.35) <0.00001 0.07 (0.03, 0.20) <0.00001
South Africa 30 (20) 1.45 (1.22, 1.74) 0.00 (0.00, 0.01) 5.65 (5.18, 6.16) 0.05 (0.02, 0.15)
Ghana 30 (20) 3.12 (1.53, 6.38) 0.00 (0.00, 0.01) 11.17 (9.69, 12.87) 1.56 (1.01, 2.42)
Jamaica 30 (20) 0.96 (0.77, 1.19) 0.01 (0.00, 0.04) 9.24 (8.37, 10.19) 2.43 (1.82, 3.25)
Seychelles 30 (20) 2.56 (2.26, 2.90) 0.47 (0.21, 1.06) 16.29 (14.93, 17.77) 28.47 (23.03, 35.18)
Age group
<35 years 72 (48) 1.46 (1.07, 1.99) 0.64 0.02 (0.01, 0.04) 0.09 8.13 (7.17, 9.22) 0.53 0.81 (0.41, 1.61) 0.22
≥35 years 78 (52) 1.64 (1.35, 1.99) 0.04 (0.02, 0.07) 8.32 (7.26, 9.53) 0.88 (0.44, 1.75)
Sex
Male 74 (49) 1.68 (1.41, 2.00) 0.35 0.03 (0.02, 0.06) 0.43 8.94 (7.93, 10.07) 0.21 1.61 (0.88, 2.94) 0.13
Female 76 (51) 1.44 (1.05, 1.96) 0.02 (0.01, 0.05) 7.59 (6.59, 8.73) 0.45 (0.22, 0.94)
Marital Status
Married/living as married 74 (49) 1.97 (1.57, 2.48) 0.02 0.02 (0.01, 0.04) 0.38 9.48 (8.39, 10.71) 0.007 1.40 (0.74, 2.65) 0.08
Not married* 76 (51) 1.22 (0.94, 1.60) 0.03 (0.02, 0.06) 7.17 (6.28, 8.18) 0.52 (0.25, 1.06)
Education
≤11 years 83 (55) 1.84 (1.39, 2.44) 0.03 0.01 (0.01, 0.02) 0.03 9.09 (8.20, 10.09) 0.23 0.90 (0.51, 1.60) 0.004
>11 years 67 (45) 1.25 (1.03, 1.52) 0.07 (0.04, 0.14) 7.27 (6.20, 8.52) 0.78 (0.35, 1.78)
Paid Employment (past month)
Yes 95 (63) 1.71 (1.42, 2.06) 0.81 0.05 (0.03, 0.09) <0.00001 9.63 (8.60, 10.79) <0.00001 2.24 (1.33, 3.80) <0.00001
No 55 (37) 1.31 (0.90, 1.90) 0.01 (0.00, 0.02) 6.26 (5.48, 7.15) 0.16 (0.07, 0.34)
Employment type
Non-manual labor 37 (25) 1.07 (0.78, 1.45) 0.12 0.10 (0.04, 0.22) 0.22 7.18 (5.67, 9.09) 0.38 0.76 (0.25, 2.32) 0.22
Skilled manual labor 16 (11) 1.39 (1.03, 1.88) 0.03 (0.01, 0.13) 7.73 (6.08, 9.81) 0.63 (0.13, 3.12)
Unskilled manual labor 92 (61) 1.87 (1.45, 2.41) 0.02 (0.01, 0.03) 9.02 (8.12, 10.03) 1.10 (0.63, 1.93)
Missing 5 (3) 1.01 (0.45, 2.31) 0.02 (0.00, 0.35) 5.01 (2.77, 9.09) 0.04 (0.00, 2.76)
Cigarette smoking
Smoker (≥1/day for year) 27 (18) 1.58 (1.28, 1.96) 0.67 0.13 (0.04, 0.37) 0.0008 6.34 (5.12, 7.85) 0.03 0.20 (0.06, 0.74) 0.05
Occasional smoker 8 (5) 2.22 (1.59, 3.10) 0.05 (0.00, 1.30) 12.09 (8.03, 18.20) 5.96 (0.56, 63.89)
Ex-smoker (for at least 1 year) 5 (3) 1.61 (0.61, 4.26) 0.01 (0.00, 0.27) 8.79 (5.68, 13.60) 2.21 (0.23, 21.52)
Never-smoker 110 (73) 1.50 (1.18, 1.90) 0.02 (0.01, 0.03) 8.50 (7.63, 9.47) 1.00 (0.59, 1.71)
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0Table 3 Geometric mean (95% confidence interval) blood metals concentrations by participant characteristics (Continued)
Alcohol Use (≥12 drinks/year)
Yes 83 (55) 1.42 (1.10, 1.84) 0.06 0.05 (0.03, 0.09) 0.002 8.94 (7.88, 10.15) 0.031 1.59 (0.84, 3.01) 0.006
No/Missing 67 (45) 1.72 (1.34, 2.22) 0.01 (0.01, 0.02) 7.41 (6.49, 8.47) 0.39 (0.19, 0.78)
Fish Intake (≥1 serving/day)
Yes 80 (53.3) 2.13 (1.72, 2.65) 0.003 0.46 (0.02, 0.09) 0.0009 10.59 (9.40, 11.93) <0.00001 2.85 (1.72, 4.72) 0.0002
No 70 (46.7) 1.07 (0.82, 1.41) 0.01 (0.01, 0.03) 6.16 (5.52, 6.88) 0.21 (0.10, 0.44)
Physical Activity
<21.5 mins/day 109 (73) 1.39 (1.11, 1.75) 0.62 0.03 (0.02, 0.05) 0.98 7.87 (7.02, 8.82) 0.36 0.79 (0.44, 1.41) 0.68
≥21.5 mins/day 41 (27) 2.06 (1.61, 2.64) 0.03 (0.01, 0.06) 9.25 (7.98, 10.73) 1.02 (0.44, 2.40)
Weight group
Underweight, BMI<18.5 6 (4) 1.83 (1.21, 2.77) 0.61 0.00 (0.00, 0.01) 0.47 8.06 (5.02, 12.92) 0.11 0.39 (0.00, 31.81) 0.04
Normal weight, BMI 18.5 to <25 70 (47) 1.62 (1.17, 2.26) 0.03 (0.02, 0.06) 8.74 (7.62, 10.01) 0.91 (0.48, 1.75)
Overweight, BMI ≥25 to <30 30 (20) 1.67 (1.24, 2.24) 0.01 (0.00, 0.05) 9.55 (7.91, 11.53) 2.38 (0.86, 6.59)
Obese, BMI ≥30 44 (29) 1.34 (1.04, 1.73) 0.04 (0.02, 0.09) 6.77 (5.66, 8.10) 0.41 (0.16, 1.09)
*Not married includes: widowed, divorced, separated, and never married.
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0Table 4 Unadjusted associations between metals exposures and cardiometabolic risk factors
Lead (μg/dL) Cadmium (μg/L) Arsenic (μg/L) Mercury (μg/L)
Cardiometabolic risk factor N (%) GM (95% CI) p-value GM (95% CI) p-value GM (95% CI) p-value GM (95% CI) p-value
Overweight, BMI ≥25
Yes 74 (49.3) 1.46 (1.21, 1.77) 0.53 0.03 (0.01, 0.05) 0.84 7.78 (6.80, 8.90) 0.24 0.84 (0.41, 1.73) 0.98
No 76 (50.7) 1.64 (1.21, 2.22) 0.03 (0.01, 0.05) 8.68 (7.64, 9.87) 0.85 (0.44, 1.64)
Obese, BMI ≥30
Yes 44 (29.3) 1.34 (1.04, 1.73) 0.31 0.04 (0.02, 0.09) 0.18 6.77 (5.66, 8.10) 0.008 0.41 (0.16, 1.09) 0.06
No 106 (70.7) 1.65 (1.31, 2.08) 0.02 (0.01, 0.04) 8.92 (8.03, 9.90) 1.14 (0.66, 1.97)
Waist Circumference ≥94 cm
(males) or ≥80 cm (females)
Yes 74 (49.3) 1.49 (1.21, 1.84) 0.69 0.03 (0.02, 0.07) 0.31 7.35 (6.40, 8.44) 0.02 0.55 (0.26, 1.18) 0.08
No 76 (50.7) 1.61 (1.20, 2.15) 0.02 (0.01, 0.04) 9.18 (8.15, 10.34) 1.29 (0.72, 2.32)
Glucose ≥100 mg/dL (fasting)
Yes 51 (34.0) 2.30 (1.78, 2.98) 0.002 0.06 (0.03, 0.14) 0.009 9.70 (8.19, 11.48) 0.01 1.62 (0.70, 3.76) 0.06
No 99 (66.0) 1.26 (1.01, 1.59) 0.02 (0.01, 0.03) 7.56 (6.79, 8.41) 0.61 (0.34, 1.08)
LDL cholesterol ≥2.59 mmol/L
Yes 101 (67.3) 1.51 (1.28, 1.77) 0.66 0.03 (0.02, 0.06) 0.11 8.42 (7.56, 9.38) 0.47 1.25 (0.71, 2.21) 0.02
No 49 (32.7) 1.64 (1.05, 2.56) 0.02 (0.01, 0.03) 7.84 (6.56, 9.36) 0.38 (0.16, 0.90)
Triglycerides ≥1.7 mmol/L
Yes 45 (30.0) 1.14 (0.90, 1.46) 0.05 0.02 (0.01, 0.04) 0.37 8.43 (7.33, 9.68) 0.73 1.13 (0.59, 2.17) 0.44
No 105 (70.0) 1.76 (1.40, 2.23) 0.03 (0.02, 0.05) 8.14 (7.23, 9.17) 0.75 (0.40, 1.41)
HDL cholesterol <1.03 (males)
or <1.29 (females) mmol/L
Yes 47 (31.3) 1.69 (1.06, 2.71) 0.51 0.01 (0.01, 0.03) 0.06 8.27 (6.83, 10.00) 0.94 0.39 (0.16, 0.97) 0.04
No 103 (68.7) 1.49 (1.27, 1.74) 0.04 (0.02, 0.06) 8.21 (7.39, 9.11) 1.20 (0.69, 2.10)
Triglyceride/HDL ratio >3.5
(males) or >2.5 (females)
Yes 55 (36.7) 1.41 (1.17, 1.71) 0.44 0.04 (0.02, 0.08) 0.27 10.69 (9.55, 11.97) <0.00001 4.49 (2.78, 7.26) <0.00001
No 95 (63.3) 1.64 (1.26, 2.13) 0.02 (0.01, 0.04) 7.07 (6.26, 7.97) 0.32 (0.17, 0.61)
C-reactive protein ≥10 mg/L
Yes 43 (28.7) 1.14 (0.93, 1.40) 0.06 0.01 (0.01, 0.03) 0.03 8.79 (7.78, 9.92) 0.37 1.30 (0.66, 2.54) 0.27
No 107 (71.3) 1.75 (1.38, 2.21) 0.04 (0.02, 0.06) 8.01 (7.10, 9.03) 0.71 (0.38, 1.32)
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0Table 4 Unadjusted associations between metals exposures and cardiometabolic risk factors (Continued)
Systolic ≥130 mmHg
Yes 24 (16.0) 1.56 (1.24, 1.96) 0.97 0.04 (0.01, 0.16) 0.40 7.08 (5.44, 9.21) 0.16 0.76 (0.22, 2.64) 0.85
No 126 (84.0) 1.55 (1.25, 1.91) 0.02 (0.02, 0.04) 8.46 (7.67, 9.34) 0.86 (0.51, 1.46)
Diastolic ≥85 mmHg
Yes 23 (15.3) 1.69 (1.23, 2.32) 0.68 0.03 (0.01, 0.14) 0.63 6.26 (4.80, 8.16) 0.02 0.49 (0.14, 1.77) 0.35
No 127 (84.7) 1.53 (1.24, 1.87) 0.03 (0.02, 0.04) 8.64 (7.85, 9.52) 0.93 (0.55, 1.57)
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0Table 5 Adjusted* associations between metals (dichotomized at median) and cardiometabolic risk factors
Lead (>1.66 μg/dL) Cadmium (>0.008 μg/L) Arsenic (>8.48 μg/L) Mercury (>1.49 μg/L)
Core model Fully-adjusted Core model Fully-adjusted Core model Fully-adjusted Core model Fully-adjusted
Cardiometabolic risk factor N (%) OR (95% CI)* OR (95% CI)** OR (95% CI)* OR (95% CI)** OR (95% CI)* OR (95% CI)** OR (95% CI)* OR (95% CI)**
Overweight, BMI ≥25 74 (49.3) 0.51 (0.24, 1.08) 0.60 (0.27, 1.36) 0.84 (0.43, 1.64) 0.71 (0.33, 1.52) 0.27 (0.10, 0.77) 0.27 (0.09, 0.81) 1.68 (0.61, 4.63) 1.73 (0.61, 4.91)
Obese, BMI ≥30 44 (29.3) 1.06 (0.45, 2.51) 1.54 (0.58, 4.11) 1.81 (0.83, 3.94) 1.89 (0.78, 4.61) 0.76 (0.24, 2.38) 0.86 (0.24, 3.07) 1.98 (0.61, 6.40) 1.98 (0.58, 6.74)
Waist Circumference ≥94
(males), ≥80 (females) cm
74 (49.3) 0.87 (0.37, 2.09) 1.40 (0.51, 3.83) 1.61 (0.72, 3.62) 2.00 (0.76, 5.27) 0.47 (0.15, 1.50) 0.54 (0.15, 1.95) 1.51 (0.46, 4.99) 1.47 (0.43, 5.00)
Glucose ≥100 mg/dL (fasting) 51 (34.0) 3.25 (1.48, 7.12) 3.95 (1.63, 9.58) 2.08 (1.03, 4.21) 1.69 (0.77, 3.68) 2.97 (1.03, 8.57) 4.10 (1.15, 14.59) 1.96 (0.68, 5.67) 1.96 (0.64, 5.98)
LDL cholesterol ≥2.59 mmol/L 101 (67.3) 0.64 (0.29, 1.39) 0.68 (0.29, 1.60) 1.38 (0.67, 2.82) 0.86 (0.37, 1.97) 0.46 (0.16, 1.36) 0.39 (0.12, 1.28) 2.09 (0.73, 5.99) 1.76 (0.59, 5.18)
Triglycerides ≥1.7 mmol/L 45 (30.0) 0.12 (0.05, 0.31) 0.09 (0.03, 0.25) 0.40 (0.18, 0.86) 0.39 (0.16, 0.95) 0.57 (0.20, 1.63) 0.52 (0.17, 1.61) 1.34 (0.45, 4.02) 1.17 (0.36, 3.77)
HDL cholesterol <1.03 (males),
<1.29 (females) mmol/L
47 (31.3) 2.36 (1.00, 5.58) 1.93 (0.74, 5.02) 0.62 (0.30, 1.31) 0.64 (0.28, 1.50) 7.15 (1.99, 25.70) 5.85 (1.48, 23.07) 0.45 (0.14, 1.43) 0.51 (0.16, 1.65)
Triglyceride/HDL ratio >3.5
(males), >2.5 (females)
55 (36.7) 0.14 (0.05, 0.44) 0.14 (0.04, 0.48) 0.43 (0.16, 1.15) 0.53 (0.18, 1.55) 0.49 (0.16, 1.52) 0.56 (0.16, 1.94) 1.28 (0.39, 4.25) 1.15 (0.31, 4.32)
C-reactive protein ≥10 mg/L 43 (28.7) 0.15 (0.06, 0.39) 0.13 (0.04, 0.36) 0.20 (0.08, 0.49) 0.28 (0.10, 0.75) 0.38 (0.13, 1.12) 0.45 (0.14, 1.44) 1.21 (0.39, 3.74) 1.14 (0.33, 3.98)
Systolic ≥130 mmHg 24 (16.0) 1.50 (0.56, 4.03) 1.69 (0.55, 5.15) 1.12 (0.546 2.76) 0.85 (0.30, 2.38) 0.36 (0.09, 1.39) 0.38 (0.08, 1.81) 2.21 (0.54, 9.04) 2.73 (0.56, 13.18)
Diastolic ≥85 mmHg 23 (15.3) 2.07 (0.69, 6.22) 2.20 (0.59, 8.16) 0.76 (0.29, 2.00) 0.46 (0.15, 1.41) 0.21 (0.05, 0.97) 0.16 (0.03, 0.90) 2.24 (0.47, 10.71) 3.50 (0.59, 20.68)
*Adjusted for age, sex, site location.
**Adjusted for age, sex, site location, marital status, education, paid employment, smoking, alcohol use, and fish intake.
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0Table 6 Adjusted* associations between metals (dichotomized at median) and cardiometabolic risk factors, controlling for percent body fat (%BF)
Lead (>1.66 μg/dL) Cadmium (>0.008 μg/L) Arsenic (>8.48 μg/L) Mercury (>1.49 μg/L)
Core model
plus %BF
Fully-adjusted
plus %BF
Core model
plus %BF
Fully-adjusted
plus %BF
Core model
plus %BF
Fully-adjusted
plus %BF
Core model
plus %BF
Fully-adjusted
plus %BF
Cardiometabolic risk factor N (%) OR (95% CI)* OR (95% CI)** OR (95% CI)* OR (95% CI)** OR (95% CI)* OR (95% CI)** OR (95% CI)* OR (95% CI)**
Overweight, BMI ≥25 74 (49.3) 0.90 (0.34, 2.40) 0.88 (0.31, 2.51) 0.55 (0.23, 1.33) 0.44 (0.17, 1.15) 0.48 (0.12, 1.87) 0.36 (0.08, 1.61) 3.35 (0.82, 13.67) 3.24 (0.80, 13.12)
Obese, BMI ≥30 44 (29.3) 2.33 (0.73, 7.43) 2.70 (0.75, 9.75) 2.04 (0.78, 5.33) 1.99 (0.64, 6.12) 1.68 (0.37, 7.72) 1.43 (0.28, 7.23) 3.37 (0.67, 16.86) 4.18 (0.82, 21.31)
Waist Circumference ≥94 cm
(males) or ≥80 cm (females)
74 (49.3) 2.23 (0.68, 7.24) 4.53 (1.06, 19.48) 1.09 (0.40, 2.95) 1.40 (0.45, 4.42) 1.19 (0.25, 5.60) 2.39 (0.38, 15.11) 2.91 (0.55, 15.40) 2.76 (0.52, 14.76)
Glucose ≥100 mg/dL (fasting) 51 (34.0) 4.82 (2.01, 11.53) 4.99 (1.97, 12.69) 2.01 (0.98, 4.13) 1.60 (0.72, 3.56) 4.81 (1.48, 15.58) 5.62 (1.49, 21.19) 2.12 (0.71, 6.33) 2.10 (0.66, 6.64)
LDL cholesterol ≥2.59 mmol/L 101 (67.3) 0.78 (0.35, 1.76) 0.77 (0.32, 1.86) 1.25 (0.60, 2.62) 0.75 (0.32, 1.76) 0.64 (0.21, 1.94) 0.50 (0.15, 1.71) 2.15 (0.73, 6.33) 1.78 (0.58, 5.51)
Triglycerides ≥1.7 mmol/L 45 (30.0) 0.12 (0.05, 0.32) 0.09 (0.03, 0.26) 0.38 (0.17, 0.83) 0.36 (0.15, 0.90) 0.63 (0.22, 1.84) 0.58 (0.18, 1.84) 1.37 (0.45, 4.14) 1.22 (0.38, 3.93)
HDL cholesterol <1.03 (males)
or <1.29 (females) mmol/L
47 (31.3) 2.64 (1.08, 6.50) 2.10 (0.79, 5.61) 0.60 (0.29, 1.2) 0.61 (0.26, 1.44) 9.81 (2.41, 39.88) 8.02 (1.84, 35.01) 0.44 (0.14, 1.41) 0.50 (0.15, 1.63)
Triglyceride/HDL ratio >3.5
(males) or >2.5 (females)
55 (36.7) 0.14 (0.04, 0.43) 0.15 (0.04, 0.51) 0.42 (0.16, 1.13) 0.53 (0.18, 1.53) 0.51 (0.6, 1.62) 0.61 (0.17, 2.15) 1.31 (0.39, 4.36) 1.19 (0.32, 4.49)
C-reactive protein ≥10 mg/L 43 (28.7) 0.15 (0.06, 0.39) 0.13 (0.05, 0.38) 0.19 (0.08, 0.47) 0.27 (0.10, 0.73) 0.38 (0.12, 1.17) 0.50 (0.16, 1.62) 1.22 (0.39, 3.79) 1.14 (0.33, 3.96)
Systolic ≥130 mmHg 24 (16.0) 1.67 (0.60, 4.64) 1.77 (0.57, 5.45) 1.10 (0.45, 2.70) 0.80 (0.28, 2.28) 0.38 (0.10, 1.48) 0.38 (0.08, 1.82) 2.27 (0.55, 9.38) 2.79 (0.57, 13.68)
Diastolic ≥85 mmHg 23 (15.3) 2.35 (0.75, 7.37) 2.37 (0.62, 9.07) 0.74 (0.28, 1.96) 0.39 (0.12, 1.26) 0.22 (0.05, 1.00) 0.15 (0.03, 0.91) 2.30 (0.47, 11.15) 4.22 (0.67, 26.39)
*Adjusted for age, sex, site location, and percent body fat (%BF).
**Adjusted for age, sex, site location, marital status, education, paid employment, smoking, alcohol use, fish intake, and percent body fat (%BF).
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biological mechanisms of effect.
It is unclear whether adiposity may be a mediator, modi-
fier, or outcome as a result of exposure to environmental
chemicals, therefore, we presented the main outcome ana-
lyses with and without adjustment for adiposity. In most
cases, the observed associations were stronger after adjust-
ment for percent body fat. Adipose tissue is now recog-
nized as an important endocrine organ responsible for
maintaining homeostasis or making physiological adap-
tations in response to dietary lipids, including increased
inflammation and insulin resistance [53]. Adipocytes se-
crete substances that contribute to peripheral insulin
resistance, including adiponectin, resistin, TNF-alpha
and interleukin 6 which interfere with glucose metabolism
and exert lipotoxic effects on pancreatic beta cells [54].
However, most studies use BMI which cannot distinguish
between overall lean vs. fat mass or body fat distribution.
Future analyses in the larger METS cohort over time will be
aimed at trying to disentangle these complex associations.
Our study has several strengths including the wide geo-
graphic distribution and resultant exposure variability in
our subpopulations. By design, there is also a wide distri-
bution of factors related to social and economic develop-
ment and the subpopulations are relatively homogeneous
with respect to ancestral/genetic background [39]. African
descent is a known risk factor for cardiometabolic diseases
[55] and this study will allow us to further elucidate the
potential for gene-environment interactions in this high-
risk subgroup.
Despite these strengths, our study has several limitations:
the small sample size of this preliminary study does not
allow us to rule out chance findings or fully explore the
role of adiposity as a potential mediator or modifier of
t h e s er e l a t i o n s h i p s .T h e r em a yb es e l e c t i o nb i a sg i v e n
the unequal distribution of risk factors, such as sex and
BMI, in the randomly chosen subset of individuals at base-
line. It may be that cumulative lifetime exposure to one or
more metals, not adequately captured by blood levels mea-
sured cross-sectionally in our study, are responsible for ad-
verse health effects of exposure. Finally, we did not control
for dietary factors, other than fish intake, or measure spe-
ciated arsenic or mercury levels in these analyses.
The role of diet both in the absorption, distribution, and
metabolism of metals and in relation to the outcomes of
interest in this study cannot be underestimated. The sites
in our parent study were chosen specifically to “model
the epidemiologic transition” occurring across five diverse
countries of varying levels of social and economic devel-
opment. The changing dietary and physical activity pat-
terns worldwide are responsible for the “double burden”
of malnutrition and obesity in many developing countries
[56]. Thus, when examining the role of environmental
contaminants, micronutrient status may be an important
modifier of the effects of exposure, particularly to metals
[57-59].
Health disparities in environmental exposures have also
been widely documented [60] and environmental and oc-
cupational health risks may disproportionately associated
with social disparities, such as lower socioeconomic status,
due to co-occurring risks such as poor housing conditions,
employment conditions, and nutritional deficits. African
American race has been associated with elevated blood
lead levels independent of age and socioeconomic con-
ditions [61,62] and, in fact, social disadvantage may further
modify or exacerbate the adverse effects of environmental
exposures [63]. The concept of allostatic load suggests that
the cumulative dysregulation of biological systems due to
changing social and environmental stressors may result in
decreased effectiveness of adaptive responses and increased
risk for disease [64]. Genetic susceptibility to metals expos-
ure is also recognized [65]. Divalent metal transporter-1
(DMT1) functions in the transport of some divalent metal
ions across the plasma membrane [66,67] and racial-ethnic
differences in DMT1 expression may underlie racial dispar-
ities in blood metals levels [68].
Health disparities in endocrine diseases have recently
been reviewed by the Endocrine Society which issued a
scientific policy statement calling for multilevel inter-
ventions to reduce disparities in diabetes and endocrine
diseases [69]. Our data suggest that exposure to environ-
mental contaminants should be considered when evalu-
ating risk and designing prevention and intervention
programs. Racial disparities in health cannot be explained
solely on the basis of genetic susceptibility, poverty and ac-
cess to care, lifestyle or environmental factors [70]. While
the size of the effects of exposures to environmental
contaminants may be relatively small, their impact on a
population-level is large, given the widespread and ever-
changing distribution of environmental risk factors around
the world and potential for cumulative effects from expos-
ure to multiple pollutants simultaneously.
Conclusions
These data are suggestive of potentially important associa-
tions between blood metals concentrations and cardiomet-
abolic risk. Insights about potential biological mechanisms
underlying disparities in cardiometabolic health can be
gained from exploring differences in environmental ex-
posures. Research efforts should include environmental
factors when studying the complex etiology of cardio-
metabolic diseases which could result in targeted inter-
ventions to decrease health disparities and the associated
risks of ongoing exposures particularly in the developing
world where environmental and occupational control
policies may be lacking or inadequate to protect public
health.
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